1
|
Yuen HK and Cunningham MA: Optimal
management of fatigue in patients with systemic lupus
erythematosus: a systematic review. Ther Clin Risk Manag.
10:775–786. 2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Yap DY and Lai KN: Pathogenesis of renal
disease in systemic lupus erythematosus-The role of autoantibodies
and lymphocytes subset abnormalities. Int J Mol Sci. 16:7917–7931.
2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Mohan C and Putterman C: Genetics and
pathogenesis of systemic lupus erythematosus and lupus nephritis.
Nat Rev Nephrol. March 31–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
4
|
Rovin BH and Parikh SV: Lupus nephritis:
The evolving role of novel therapeutics. Am J Kidney Dis.
63:677–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Gopaul NK and Anggård EE: Measurement of
8-epi-PGF2alpha as a marker of lipid peroxidation in vivo by
immunoaffinity extraction and gas chromatography-mass spectrometry.
Methods Mol Biol. 225:329–342. 2003.PubMed/NCBI
|
6
|
Jiang X and Chen F: The effect of lipid
peroxides and superoxide dismutase on systemic lupus erythematosus:
A preliminary study. Clin Immunol Immunopathol. 63:39–44. 1992.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Suwannaroj S, Lagoo A, Keisler D and
McMurray RW: Antioxidants suppress mortality in the female NZB ×
NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus.
10:258–265. 2001. View Article : Google Scholar : PubMed/NCBI
|
8
|
Tewthanom K, Janwitayanujit S,
Totemchockcyakarn K and Panomvana Na Ayudhya D: The effect of high
dose of N-acetylcysteine in lupus nephritis: A case report and
literature review. J Clin Pharm Ther. 35:483–485. 2010.PubMed/NCBI
|
9
|
Holdiness MR: Clinical pharmacokinetics of
N-acetylcysteine. Clin Pharmacokinet. 20:123–134. 1991. View Article : Google Scholar : PubMed/NCBI
|
10
|
Prescott L: Oral or intravenous
N-acetylcysteine for acetaminophen poisoning? Ann Emerg Med.
45:409–413. 2005. View Article : Google Scholar : PubMed/NCBI
|
11
|
Petri M: Systemic lupus international
collaborating clinic (SLICC) revision of the ACR classification
criteria for SLE. Arthritis Rheum. 60 (Suppl 10):895–2009
|
12
|
Gladman DD, Ibañez D and Urowitz MB:
Systemic lupus erythematosus disease activity index 2000. J
Rheumatol. 29:288–291. 2002.PubMed/NCBI
|
13
|
Gergely P Jr, Grossman C, Niland B, Puskas
F, Neupane H, Allam F, Banki K, Phillips PE and Perl A:
Mitochondrial hyperpolarization and ATP depletion in patients with
systemic lupus erythematosus. Arthritis Rheum. 46:175–190. 2002.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Lai ZW, Hanczko R, Bonilla E, et al:
N-acetylcysteine reduces disease activity by blocking mammalian
target of rapamycin in T cells from systemic lupus erythematosus
patients: A randomized, double-blind, placebo-controlled trial.
Arthritis Rheum. 64:2937–2946. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Garcia RJ, Francis L, Dawood M, Lai ZW,
Faraone SV and Perl A: Attention deficit and hyperactivity disorder
scores are elevated and respond to N-acetylcysteine treatment in
patients with systemic lupus erythematosus. Arthritis Rheum.
65:1313–1318. 2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Sandilands EA and Bateman DN: Adverse
reactions associated with acetylcysteine. Clin Toxicol (Phila).
47:81–88. 2009. View Article : Google Scholar : PubMed/NCBI
|
17
|
vinh quỗc Luong K and Nguyễn LT: The
beneficial role of vitamin D in systemic lupus erythematosus (SLE).
Clin Rheumatol. 31:1423–1435. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Willis R, Seif AM, McGwin G Jr, et al:
Effect of hydroxychloroquine treatment on pro-inflammatory
cytokines and disease activity in SLE patients: Data from LUMINA
(LXXV), a multiethnic US cohort. Lupus. 21:830–835. 2012.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Brown JR and Thompson CA: Contrast-induced
acute kidney injury: The at-risk patient and protective measures.
Curr Cardiol Rep. 12:440–445. 2010. View Article : Google Scholar : PubMed/NCBI
|
20
|
Maeder M, Klein M, Fehr T and Rickli H:
Contrast nephropathy: Review focusing on prevention. J Am Coll
Cardiol. 44:1763–1771. 2004. View Article : Google Scholar : PubMed/NCBI
|
21
|
Doherty E, Oaks Z and Perl A: Increased
mitochondrial electron transport chain activity at complex I is
regulated by N-acetylcysteine in lymphocytes of patients with
systemic lupus erythematosus. Antioxid Redox Signal. 21:56–65.
2014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Schieke SM, Phillips D, McCoy JP Jr,
Aponte AM, Shen RF, Balaban RS and Finkel T: The mammalian target
of rapamycin (mTOR) pathway regulates mitochondrial oxygen
consumption and oxidative capacity. J Biol Chem. 281:27643–27652.
2006. View Article : Google Scholar : PubMed/NCBI
|